Acute Coronary Syndrome

• Acute Myocardial Infarction Toolkit
• Heart Disease: Resources for Individuals and Patients
• Acute coronary syndromes
• 2020 ESC NSTE-ACS Guidelines: Evolving Approaches and Recommendations
• 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Atherothrombosis

• 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
• Coagulation factor Xa (recombinant), inactivated-zhzo Prescribing Information
• 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Solution Set Oversight Committee
• Management of bleeding in patients receiving direct oral anticoagulants

Cardiac Imaging

• 2021AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain
• Selecting the optimal cardiac stress test

Dyslipidemia

• Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial
• An “Inclisiran First” Strategy vs Usual Care in Patients With Atherosclerotic Cardiovascular Disease
• ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways
• HPS3/TIMI55-REVEAL: Long-term Safety and Efficacy of Anacetrapib
• ROSE Study: Obicetrapib and High-Intensity Statin Therapy
• Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?
• Bempedoic Acid for LDL-C Lowering: What Do We Know?
• Heart Disease and Stroke Statistics—2021 Update
• Identification of female-specific risk enhancers throughout the lifespan of women to improve CVD prevention
• Identification of female-specific risk enhancers throughout the lifespan of women to improve cardiovascular disease prevention
• Prescribing Information for Alirocumab
• ACC Statin Intolerance Tool
• Cholesterol Tools and Resources

Familial Chylomicronemia Syndrome (FCS)

• Qualitative development of the PROMIS Profile v1.0-Familial Chylomicronemia Syndrome (FCS) 28
• Understanding FCS – for Patients
• About FCS
• 2015-2020 Dietary Guidelines

Familial Hypercholesterolemia (FH)

• Diagnostic Criteria for Familial Hypercholesterolemia
• Familial Hypercholesterolemia: Cardiovascular Risk Stratification and Clinical Management

Heart Failure (HF)

• Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials: JACC Review Topic of the Week
• Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial
• Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF
• Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes
• 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
• Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial
• Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
• A Standardized and Comprehensive Approach to the Management of Cardiogenic Shock
• Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure
• Heart Failure: Patient Education

Hypertension

• CDC Facts About Hypertension
• Harmonization of the American College of Cardiology/American Heart Association and European Society of Cardiology/European Society of Hypertension Blood Pressure/Hypertension Guidelines: Comparison, Reflections, and Recommendations
• High Blood Pressure Information for Patients
• Treatment of resistant hypertension
• Million Hearts® Hypertension Control: Action Steps for Clinicians

Hypertriglyceridemia

• Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT
• Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results
• 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee
• REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial. AHA 2018.
• Fish and Omega-3 Fatty Acids

Hypertrophic Cardiomyopathy (HCM)

• Provider Tools: AHA HCM Educational Resources
• Partnership Between Primary Care and Centers of Excellence for HCM
• Provider Tools: Genetic Testing and Counseling for HCM
• Systematic Review of Current Diagnostic and Treatment Methods for HCM
• Talking With Patients About Hypertrophic Cardiomyopathy
• 2024 AHA/ACC/Multisociety Guideline for the Management of HCM
• Mavacamten Prescribing Information
• Mavacamten REMS (Risk Evaluation and Mitigation Strategy)
• Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy
• VALOR-HCM: A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy
• Risk Stratification in HCM
• Diagnosis and Evaluation of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review
• Associations of Race and Ethnicity With Presentation and Outcomes of Hypertrophic Cardiomyopathy
• Patient Information: Hypertrophic Cardiomyopathy (HCM)
• Hypertrophic Cardiomyopathy Association (HCMA)
• Patient Information: Hypertrophic Cardiomyopathy (HCM)
• Encouraging Shared Decision Making in HCM
• Patient Info: HCM Action Plan
• Patient Info: HCM Fact Sheets
• Patient Info: HCM Genetic Testing
• Patient Info: Hypertrophic Cardiomyopathy

Lipoprotein (a) [Lp(a)]

• A Focused Update to the 2019 NLA Scientific Statement on Use of Lipoprotein(a) in Clinical Practice
• Patient Resource: What is Lipoprotein(a)?
• Patient Resource: Treating High Lp(a)
• Assessing Risk: Infographic on Lp(a) Screening
• Emerging RNA Therapeutics to Lower Blood Levels of Lp(a)
• Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease

Venous Thromboembolism (VTE)

• American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism
• Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report
• What is Venous Thromboembolism (VTE)?
• Wells’ Criteria for Pulmonary Embolism